736 related articles for article (PubMed ID: 28415828)
21. Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives.
Costanzi E; Simioni C; Conti I; Laface I; Varano G; Brenna C; Neri LM
J Cell Physiol; 2021 Apr; 236(4):2505-2518. PubMed ID: 32989768
[TBL] [Abstract][Full Text] [Related]
22. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.
Reiter RJ; Rosales-Corral SA; Tan DX; Acuna-Castroviejo D; Qin L; Yang SF; Xu K
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420185
[TBL] [Abstract][Full Text] [Related]
23. Distribution and density of melatonin receptors in human main pancreatic islet cell types.
Zibolka J; Bazwinsky-Wutschke I; Mühlbauer E; Peschke E
J Pineal Res; 2018 Aug; 65(1):e12480. PubMed ID: 29464840
[TBL] [Abstract][Full Text] [Related]
24. The potential therapeutic actions of melatonin in colorectal cancer.
Chok KC; Ng CH; Koh RY; Ng KY; Chye SM
Horm Mol Biol Clin Investig; 2019 May; 39(1):. PubMed ID: 31141480
[TBL] [Abstract][Full Text] [Related]
25. Basic mechanisms involved in the anti-cancer effects of melatonin.
Mediavilla MD; Sanchez-Barcelo EJ; Tan DX; Manchester L; Reiter RJ
Curr Med Chem; 2010; 17(36):4462-81. PubMed ID: 21062257
[TBL] [Abstract][Full Text] [Related]
26. Molecular targets for the management of gastrointestinal cancer using melatonin, a natural endogenous body hormone.
Kohandel Z; Farkhondeh T; Aschner M; Samarghandian S
Biomed Pharmacother; 2021 Aug; 140():111782. PubMed ID: 34087693
[TBL] [Abstract][Full Text] [Related]
27. Role and Therapeutic Potential of Melatonin in Various Type of Cancers.
Gurunathan S; Qasim M; Kang MH; Kim JH
Onco Targets Ther; 2021; 14():2019-2052. PubMed ID: 33776451
[TBL] [Abstract][Full Text] [Related]
28. Melatonin in cancer management: progress and promise.
Jung B; Ahmad N
Cancer Res; 2006 Oct; 66(20):9789-93. PubMed ID: 17047036
[TBL] [Abstract][Full Text] [Related]
29. Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth.
Hill SM; Cheng C; Yuan L; Mao L; Jockers R; Dauchy B; Blask DE
Curr Aging Sci; 2013 Feb; 6(1):125-33. PubMed ID: 23895529
[TBL] [Abstract][Full Text] [Related]
30. Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved.
Bastani S; Akbarzadeh M; Rastgar Rezaei Y; Farzane A; Nouri M; Mollapour Sisakht M; Fattahi A; Akbarzadeh M; Reiter RJ
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639215
[TBL] [Abstract][Full Text] [Related]
31. Melatonin Receptor Signaling: Impact of Receptor Oligomerization on Receptor Function.
Oishi A; Cecon E; Jockers R
Int Rev Cell Mol Biol; 2018; 338():59-77. PubMed ID: 29699692
[TBL] [Abstract][Full Text] [Related]
32. Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics.
Pariente R; Bejarano I; Espino J; Rodríguez AB; Pariente JA
Cancer Chemother Pharmacol; 2017 Nov; 80(5):985-998. PubMed ID: 28956121
[TBL] [Abstract][Full Text] [Related]
33. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy.
Targhazeh N; Reiter RJ; Rahimi M; Qujeq D; Yousefi T; Shahavi MH; Mir SM
Biochimie; 2022 Nov; 202():34-48. PubMed ID: 35752221
[TBL] [Abstract][Full Text] [Related]
34. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal.
Blask DE; Dauchy RT; Sauer LA
Endocrine; 2005 Jul; 27(2):179-88. PubMed ID: 16217131
[TBL] [Abstract][Full Text] [Related]
35. The validity of melatonin as an oncostatic agent.
Panzer A; Viljoen M
J Pineal Res; 1997 May; 22(4):184-202. PubMed ID: 9247204
[TBL] [Abstract][Full Text] [Related]
36. Melatonin and its mechanism of action in the female reproductive system and related malignancies.
Ezzati M; Velaei K; Kheirjou R
Mol Cell Biochem; 2021 Aug; 476(8):3177-3190. PubMed ID: 33864572
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of melatonin anticancer effects.
Hill SM; Frasch T; Xiang S; Yuan L; Duplessis T; Mao L
Integr Cancer Ther; 2009 Dec; 8(4):337-46. PubMed ID: 20050373
[TBL] [Abstract][Full Text] [Related]
38. Melatonin, a natural programmed cell death inducer in cancer.
Sánchez-Hidalgo M; Guerrero JM; Villegas I; Packham G; de la Lastra CA
Curr Med Chem; 2012; 19(22):3805-21. PubMed ID: 22612707
[TBL] [Abstract][Full Text] [Related]
39. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy [Biochimie 200 (2022) 44-59].
Targhazeh N; Reiter RJ; Rahimi M; Qujeq D; Yousefi T; Shahavi MH; Mir SM
Biochimie; 2022 Sep; 200():44-59. PubMed ID: 35618158
[No Abstract] [Full Text] [Related]
40. Insights on Melatonin as an Active Pharmacological Molecule in Cancer Prevention: What's New?
Bjørklund G; Rajib SA; Saffoon N; Pen JJ; Chirumbolo S
Curr Med Chem; 2019; 26(34):6304-6320. PubMed ID: 29714136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
